Largactil Im (Chlorpromazine Hydrochloride)

Chlorpromazine exerts its therapeutic effect primarily by blocking dopamine D2 receptors in the brain, which reduces dopaminergic activity responsible for psychotic symptoms. In addition, it antagonizes histamine H1, muscarinic acetylcholine, and alpha‑adrenergic receptors, producing sedation, anticholinergic effects, and vasodilation that contribute to its overall clinical profile.

The dosage of Largactil Im is determined by the prescribing clinician based on the patient’s condition, severity, age, and response to therapy. The prescriber will select an appropriate strength and frequency, typically administered as a single intramuscular injection or repeated doses as clinically indicated.

Safety data for chlorpromazine in pregnancy and lactation are limited. It is generally classified as a drug to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Largactil Im. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with newer atypical antipsychotics, chlorpromazine has a broader receptor profile, affecting dopamine, histamine, muscarinic, and adrenergic systems, which can result in a higher incidence of sedation and anticholinergic side effects. However, it remains an effective, cost‑efficient option for acute symptom control, especially when rapid intramuscular administration is needed.

Largactil Im should be stored at ambient temperature, preferably below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight, and extreme temperature fluctuations to maintain product stability and potency until the point of use.

Largactil Im is administered by deep intramuscular injection, typically into the gluteal muscle. The injection should be performed by a qualified healthcare professional using aseptic technique. The volume and concentration of the dose are determined by the prescriber, and the injection site should be rotated if multiple doses are required.

The most serious adverse reactions include neuroleptic malignant syndrome, severe hypotension, cardiac arrhythmias such as QT prolongation, agranulocytosis, tardive dyskinesia, and seizures. Patients should be monitored closely for signs of these conditions, and immediate medical attention is required if they occur.

Largactil Im is contraindicated in patients with known hypersensitivity to chlorpromazine or any phenothiazine, those with severe central nervous system depression, and individuals with a history of malignant hyperthermia. Caution is also advised in patients with uncontrolled cardiovascular disease, glaucoma, or severe hepatic impairment.